However, this study aimed on the identification of reversion BRCA1/2 mutations that could be responsible for acquiring the chemotherapy resistance, not on the overall screening of both germline and somatic alterations in a large cohort of unselected ovarian cancer patients. The gene discussed is BRCA1; the disease is ovarian cancer.